Cytovation’s product pipeline offers potentially new treatments for multiple cancers where no satisfactory options currently exist.
CyPep-01 selectively targets and lyses tumour cells and induces a long-lasting tumour-specific immune response while leaving healthy cells intact.
CyPep-O1 is a novel proprietary peptide currently in pre-clinical development as a potential new treatment for multiple cancers.
Office: +47 55 97 09 56
Mobil: +47 904 74 508
10 John Street
Office: +44 207 067 4300
© 2018 Cytovation AS|All Rights Reserved